Immuron: Receives important FDA guidance for new drug development
- Biopharma company Immuron has received U.S. Food and Drug Administration (FDA) guidance for a new drug designed to treat diarrhoea
- Immuron’s research partner, Naval Medical Research Centre, met with the FDA on behalf of the company to discuss the new drug
- The company also pleased to inform shareholders that the manufacturing program is proceeding as planned
- Then the FDA gave the partners guidance around the drug’s chemistry, manufacturing, controls, and testing specifications
- According to Immuron CEO Dr Jerry Kanellos, this is an important milestone for the development of any new drug for therapeutic evaluation
- Shares in Immuron gained 11.36 per cent today to close worth 24 cents each